A ANI PHARMACEUTICALS INC
| Market Cap | $1.67B |
| P/E Ratio | 22.40 |
| Forward P/E | 7.16 |
| Dividend Yield | — |
| Beta | 0.46 |
| 52W Range | $56.71 - $99.50 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 27 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Mutz ChristopherHEAD OF RARE DISEASE | Sale | 3,162 | $71.64 | $226.53K | 13 Mar 2026 | 13 Mar 2026 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $72.62 | $36.31K | 13 Mar 2026 | 13 Mar 2026 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Sale | 4,772 | $74.91 | $357.47K | 11 Mar 2026 | 13 Mar 2026 |
| Mutz ChristopherHEAD OF RARE DISEASE | Sale | 3,602 | $74.18 | $267.20K | 09 Mar 2026 | 06 Mar 2026 |
| Davis KristaSVP, CHIEF HR OFFICER | Sale | 5,087 | $74.13 | $377.10K | 09 Mar 2026 | 06 Mar 2026 |
| Mutz ChristopherHEAD OF RARE DISEASE | Sale | 2,121 | $74.22 | $157.42K | 06 Mar 2026 | 06 Mar 2026 |
| Davis KristaSVP, CHIEF HR OFFICER | Sale | 1,485 | $75.00 | $111.38K | 06 Mar 2026 | 06 Mar 2026 |
| CAREY STEPHEN P.SVP & CFO | Sale | 3,312 | $75.42 | $249.79K | 05 Mar 2026 | 05 Mar 2026 |
| CAREY STEPHEN P.SVP & CFO | Sale | 4,000 | $75.56 | $302.24K | 05 Mar 2026 | 05 Mar 2026 |
| Gutwerg OriSVP, GENERICS | Sale | 2,060 | $76.50 | $157.59K | 03 Mar 2026 | 04 Mar 2026 |
| Walsh Patrick D | Sale | 6,000 | $74.23 | $445.38K | 03 Mar 2026 | 03 Mar 2026 |
| Mutz ChristopherHEAD OF RARE DISEASE | Sale | 417 | $74.00 | $30.86K | 02 Mar 2026 | 04 Mar 2026 |
| Mutz ChristopherHEAD OF RARE DISEASE | Sale | 5,323 | $78.02 | $415.30K | 20 Feb 2026 | 23 Feb 2026 |
| Davis KristaSVP, CHIEF HR OFFICER | Sale | 1,730 | $77.99 | $134.92K | 20 Feb 2026 | 23 Feb 2026 |
| Davis KristaSVP, CHIEF HR OFFICER | Sale | 2,084 | $77.53 | $161.57K | 19 Feb 2026 | 23 Feb 2026 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $76.80 | $38.40K | 13 Feb 2026 | 17 Feb 2026 |
| Mutz ChristopherHEAD OF RARE DISEASE | Sale | 7,032 | $76.55 | $538.30K | 12 Feb 2026 | 17 Feb 2026 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $84.33 | $42.16K | 13 Jan 2026 | 14 Jan 2026 |
| Davis KristaSVP, CHIEF HR OFFICER | Sale | 1,622 | $82.40 | $133.65K | 18 Dec 2025 | 19 Dec 2025 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sale | 400 | $82.32 | $32.93K | 12 Dec 2025 | 12 Dec 2025 |
| TANNENBAUM RENEE P | Sale | 1,800 | $81.15 | $146.07K | 05 Dec 2025 | 09 Dec 2025 |
| Walsh Patrick D | Sale | 8,643 | $86.88 | $750.90K | 13 Nov 2025 | 17 Nov 2025 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Sale | 94 | $88.00 | $8.27K | 13 Nov 2025 | 14 Nov 2025 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sale | 400 | $87.27 | $34.91K | 13 Nov 2025 | 14 Nov 2025 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Sale | 14,642 | $89.07 | $1.30M | 12 Nov 2025 | 14 Nov 2025 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sale | 400 | $90.09 | $36.04K | 13 Oct 2025 | 14 Oct 2025 |
| Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sale | 400 | $90.09 | $36.04K | 13 Oct 2025 | 14 Oct 2025 |
Frequently Asked Questions
What is ANIP stock price today?
ANI PHARMACEUTICALS INC (ANIP) is currently trading at $74.37. The stock has a 52-week range of $56.71 to $99.50 and a market capitalization of $1.67B.
Is ANIP a good stock to buy in 2026?
ANI PHARMACEUTICALS INC has a P/E ratio of 22.4 (forward P/E: 7.2), a dividend yield of none, and 1-year performance of +25.6%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ANIP stock?
There have been 27 insider transactions for ANIP in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ANIP stock performed over the past year?
ANI PHARMACEUTICALS INC (ANIP) has returned +25.6% over the past 12 months. The stock traded between $56.71 and $99.50 during this period, and is currently at $74.37.
Which hedge funds own ANIP (ANI PHARMACEUTICALS INC)?
0 tracked hedge funds currently hold ANIP in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ANIP's market cap and valuation?
ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of $1.67B. The trailing P/E ratio is 22.4 and forward P/E is 7.2. The stock is classified in the Healthcare sector.
What is ANIP's revenue and profitability?
ANI PHARMACEUTICALS INC reported revenue of $883.37M with net income of $70.22M and a profit margin of 0.09%. The stock has a beta of 0.46.
What sector is ANIP in and who are its biggest institutional holders?
ANI PHARMACEUTICALS INC (ANIP) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.